Molecule Can Mask Cancer’s Pain, Helping the Disease Develop, Study Shows – Immuno-Oncology News
|
Molecule Can Mask Cancer’s Pain, Helping the Disease Develop, Study Shows
Immuno-Oncology News The PD-L1 molecule can mask cancer’s pain, enabling malignancies to develop and spread without sending alarms to the immune system, according to a study. Researchers from Duke University School of Medicine discovered that Opdivo (nivolumab) fights … |
Financial Times |
Big pharma turns to immunotherapy combos to beat cancer
Financial Times Merck last week became the first company to win approval to use its immunotherapy Keytruda in all patients whose tumours have a particular biological trait or “biomarker”, regardless of where the cancer is located. At Asco, it is due to present full … |
|
Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR–T cells
Business Wire (press release) “Allogeneic CAR–T cells are of increasing interest to many Pharma and BioPharma companies involved in cell-based cancer immunotherapies. We are looking to maximize the significant value of our allogeneic CAR-T assets through strategic collaborations … |